Evidence map›Paper›PMID 35453201›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria.

David M P De Oliveira, Bernhard Keller, Andrew J Hayes, Cheryl-Lynn Y Ong, Nichaela Harbison-Price, Ibrahim M El-Deeb, Gen Li, Nadia Keller, Lisa Bohlmann, Stephan Brouwer and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Disruption of zinc homeostasis reverses tigecycline resistance inFrontiers in cellular and infection microbiology · 2025
    Article
  6. Article
  7. Vancomycin Resistance inMicroorganisms · 2022
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

David M P De OliveiraAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-5085-7163
Bernhard KellerAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Andrew J HayesDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0001-8038-1656
Cheryl-Lynn Y OngAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0001-6036-6889
Nichaela Harbison-PriceAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Ibrahim M El-DeebInstitute for Glycomics, Griffith University, Gold Coast, QLD 4222, Australia.
Gen LiAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-7465-2517
Nadia KellerAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Lisa BohlmannAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Stephan BrouwerAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Andrew G TurnerAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-0882-7881
Amanda J CorkAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Thomas R JonesSchool of Earth and Environmental Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-2275-7659
David L PatersonAustralian Infectious Diseases Research Centre, UQ Centre for Clinical Research, The University of Queensland, Brisbane, QLD 4006, Australia.
Alastair G McEwanAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Mark R DaviesDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0001-6141-5179
Christopher A McDevittDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0003-1596-4841
Mark von ItzsteinInstitute for Glycomics, Griffith University, Gold Coast, QLD 4222, Australia.ORCID 0000-0001-6302-7524
Mark J WalkerAustralian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
The University of Queensland · AUThe University of Melbourne · AUGriffith University · AU

Funding

Australian Research Council FT170100006National Health and Medical Research Council APP1176180National Health and Medical Research Council APP1194130National Health and Medical Research Council APP2009677Swiss National Science Foundation P2ZHP3_184024Swiss National Science Foundation SNSF grant number P2ZHP3_191292
6 · The paper itself

Abstract

Gram-positive bacteria do not produce lipopolysaccharide as a cell wall component. As such, the polymyxin class of antibiotics, which exert bactericidal activity against Gram-negative pathogens, are ineffective against Gram-positive bacteria. The safe-for-human-use hydroxyquinoline analog ionophore PBT2 has been previously shown to break polymyxin resistance in Gram-negative bacteria, independent of the lipopolysaccharide modification pathways that confer polymyxin resistance. Here, in combination with zinc, PBT2 was shown to break intrinsic polymyxin resistance in

Indexed as

antimicrobial resistanceGram-positive bacteriaionophoresPBT2polymyxins

Identifiers

PMID35453201
PMCPMC9027797
OpenAlexW4220947443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.